Abstract: Model tetrahydropyrido [3',2':4,5]thieno [2,3-b][1,4]thiazines 9a-c were synthesized via reductive lactamization, using sodium dithionite, of the respective 2-[(carboxyalkyl)thio]-3-nitro-4,7-dihydrothieno[2,3-b]pyridine-5-carboxylic acids 7a-c. The latter derivatives were made via interaction of 2-chloro-7-cyclopropyl-3-nitro-4,7-dihydrothieno[2,3-b]pyridine-5-carboxylic acid (6) with each of α-mercaptoacetic, α-mercaptopropionic, and α-mercaptosuccinic acids and triethylamine in aqueous acetone at room temperature. The structures of 7a-7c and 9a-9c are supported by microanalytical and spectral (IR, MS, NMR) data. Compounds 9a and 9c showed potent inhibitory activity against the IGROV1 (Ovarian Cancer) cell line.
Introduction
Several substituted 4-oxothieno [2,3-b] pyridine-5-carboxylic acids (exemplified by 1 [1] , Figure 1 ) bioisosteres of fluoroquinolone antibacterials (such as ciprofloxacin), were synthesized and reported to exhibit ″good to excellent″ levels of antibacterial potency [1] [2] [3] [4] . On the other hand, thieno [2,3-b] [1,4]-thiazine derivatives (e.g. 2, Figure 1 ) are currently of interest due to their as therapeutic properties as smooth muscle relaxants [5] and as potassium channel-opening agents [6] which make them potentially useful for the treatment of various diseases, while certain thieno [2,3-b] [1, 4] thiazine-2-ones (e.g. 3) have been patented as urokinase inhibitors [7] . (1)
We became interested in condensed pyridothieno [1, 4] thiazine tricyclic systems, for which literature data are confined to only one report [8] describing the preparation and properties of pyrido [2,1-c] thieno [3,2- 
In particular, we envisaged that the hitherto undescribed tetrahydro-1H-pyrido[3',2':4,5]thieno [2,3-b] [1, 4] thiazine-8-carboxylic acids 9a-9c (Scheme 1), representing a tricyclic hybrid of 1 and 3, might exhibit interesting bioproperties such as antimicrobial and antitumor activity. Hence, the present work deals with the synthesis and properties of 9a-9c, as outlined in Scheme 1 and detailed in the Experimental section. These novel heterocyclics 9a-9c are potential bioisosteres of the recently described [1, 4] thiazino-[2,3-h]quinoline-8-carboxylic acids 10a-10c shown in Scheme 1 [9] , in which the benzene nucleus (B) is replaced by a thiophene ring. 
Results and Discussion
The synthesis of compounds 9a-9c is achieved by utilizing 2-chloro-7-cyclopropyl-3-nitro-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxylic acid (6) [2] as a common synthon, and constructing the thiazinone nucleus thereon through two-step conversions as illustrated in Scheme 1. The first step entails the preparation of the acyclic precursors 7a-7c via direct interaction of the appropriate α-mercapto-alkanoic acids with the synthon 6 in aqueous acetone containing triethylamine. This reaction follows an S N -Ar (addition-elimination) path, and is facilitated by the presence of the electronwithdrawing C(4)-keto and the C(3)-nitro groups. Reduction of 7a-7c with sodium dithionite in aqueous potassium carbonate converts the nitro group to an amino group, and is followed by spontaneous lactamization of the resultant 8-amino intermediates 8a-8c to afford good yields of the corresponding target products 9a-9c in fairly pure form. The required common synthon 6 is made accessible by nitration of 1, which in turn is prepared from 3-acetyl-2,5-dichlorothiophene according to a literature procedure [1] .
Antitumor Activity
Compounds 9 and 10 were tested using 10 µM concentration against the panel of 60 human cancer cell lines used by the National Cancer Institute (NCI, USA). The most affected cell line was IGROV1 (from Ovarian Cancer). The percentage growth inhibitions at 10 µM were 76%, 64%, 65% and 88% for compounds 9a, 9c, 10a and 10c, respectively.
Experimental
General 2,5-Dichlorothiophene, ethyl 3-(N,N-dimethylamino)acrylate and cyclopropylamine were purchased from Acros. (±)-2-Mercaptopropionic acid, (±)-2-mercaptosuccinic acid and mercaptoacetic acid were purchased from Aldrich. Melting points were determined on a Gallenkamp capillary melting point apparatus and are uncorrected.
1 H-and 13 C-NMR spectra were measured on a Bruker DPX-300 instrument with Me 4 Si as internal reference. High resolution mass spectra (HRMS) were measured in positive ion mode by Electrospray (ESI) on APEX-Qe 94 instrument. The samples were dissolved in acetonitrile, diluted in spray solution (methanol/water 1:1 v/v + 0.1% formic acid) and infused using a syringe pump with a flow of 2 uL/min. External calibration was conducted using Arginine cluster in a mass range m/z 175-871. MS/MS spectra for 7a and 7b were performed in the external Qh of the APEX-Q. For all HRMS data, the mass error was 0.00-0.50 ppm. IR spectra were recorded as KBr discs on a Nicolet Impact-400 FT-IR spectrophotometer. Elemental analyses were preformed at the Microanalytical Laboratory of the Hashemite University, Zarqa, Jordan.
2-[(Carboxymethyl)thio]-7-cyclopropyl-3-nitro-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxylic acid (7a).
Mercaptoacetic acid (0.46 g, 5 mmol) was added to a stirred solution of 2-chloro-7-cyclopropyl-3-nitro-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxylic acid (6, 1.32 g, 4.2 mmol) in aqueous acetone (1:2 v/v, 54 mL) and triethylamine (6 mL) at rt, and then kept in the dark for 7 h. The reaction mixture was then washed with chloroform (2 x 10 mL), the aqueous layer was acidified with 3N HCl and the precipitated product was collected and dried. The title compound was purified by stirring in boiling chloroform (10 mL) in which the soluble impurities are removed. 
2-[(Carboxyethyl)thio]-7-cyclopropyl-3-nitro-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxylic acid [(±)-7b]
Prepared from (±)-2-mercaptopropionic acid (0.53 g, 5 mmol) and 6 (1.32 g, 4.2 mmol) using the procedure and experimental conditions described above for the preparation of 7a. The title compound was isolated as a yellow solid which was recrystallized from chloroform. 
2-[(Carboxyl-7-cyclopropyl-3-nitro-4-oxo-4,7-dihydrothieno[2,3-b]pyridin-2-yl)thio]succinic acid [(±)-7c]
Prepared from (±)-2-mercaptosuccinic acid (0.75 g, 5 mmol) and 6 (1.32 g, 4.2 mmol) using the procedure and experimental conditions described above for the preparation of 7a. [3',2':4,5] thieno [2,3- 
6-Cyclopropyl-2,9-dioxo-2,3,6,9-tetrahydro-1H-pyrido
To a vigorously stirred suspension of 2-[(carboxymethyl)thio]-7-cyclopropyl-3-nitro-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxylic acid (7a, 0.37 g, 1 mmol) in concentrated hydrochloric acid (12 mL) was added, portionwise, stannous chloride dihydrate ( 1.13 g, 5 mmol). The mixture was stirred for 1h, then treated with water (12 mL) and was kept under stirring at rt until a clear solution was obtained. This solution was finally neutralized with aqueous sodium carbonate whereby a deep brown precipitate was formed, which was collected, washed with cold water, cold ethanol and dried. -3-methyl-2,9-dioxo-2,3,6,9-tetrahydro-1H-pyrido [3', 2' : 4,5] thieno [2,3-b] [1, 4] 
6-Cyclopropyl

3-(Carboxymethyl)-6-cyclopropyl-2,9-dioxo-2,3,6,9-tetrahydro-1H-pyrido-[3',2':4,5]thieno[2,3-b][1,4]-thiazine-8-carboxylic acid [ (±)-9c]
This compound was prepared via reductive cyclization of (±)-2-[(5-carboxy-7-cyclopropyl-3-nitro-4-oxo-4,7-dihydrothieno[2,3-b]pyridin-2-yl)thio]succinic acid [(±)-7c, 0.43 g, 1 mmol] using stannous chloride dihydrate (1.13 g, 5 mmol), and following the same procedure and experimental conditions described above for the preparation of 9a. The title compound was isolated as a yellow solid which was washed with ethanol and dried. 
